The risk of breast cancer related to CD44 polymorphism was further examined with stratification by age, family history of breast cancer, pathological type, clinical stage, estrogen/progesterone receptor status (ER, PR), and Her2 expression. This evidence concerns the gene ERBB2 and breast cancer.